StockWatch
·

BLACK ROSE INDUSTRIES LTD. Q2 FY27 Results

BLACKROSEQ2 FY27 Results
Filing
Result:Good· Market: Surged#Margin expansion#Record quarter#Base effect
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue87.681.6%4.4%
Total Income91.251.2%8.2%
Expenditure76.961.3%1.6%
PBT14.291.0%134.7%
Net Profit10.490.9%136.9%
OPM13.81%2.34pp5.22pp
NPM11.49%0.04pp6.24pp
EPS2.061.0%136.8%
View full financials

Chemicals: revenue growth stalled at just 4.4% YoY while the 137% PAT jump is entirely a margin-expansion story (OPM 8.6%→13.8%, NPM 5.3%→11.5%) off a depressed prior-year base, so core growth caps it below very_good despite the highest PAT in six quarters.

Q2 FY-2027 RESULTS · BLACKROSE

Black Rose Industries: consolidated PAT +137% YoY on margin rebound, revenue up 4%

PAT +136.87% YoY · revenue +4.41% · margins expanding

06 Nov 2026 · 3 min read
Revenue

₹87.68 Cr

+4.41% YoY

PAT (consolidated)

₹10.49 Cr

+136.87% YoY

Net margin

11.5%

+6.3pp YoY

EPS

₹2.06

Black Rose Industries' consolidated PAT for Q2 FY27 (quarter ended 30 September 2026) came in at ₹10.49 Cr, up 137% year-on-year from ₹4.43 Cr in Q2 FY26, while revenue from operations grew a much more modest 4.4% YoY to ₹87.68 Cr (₹83.98 Cr a year ago). Sequentially the print was flat — PAT up just 0.9% QoQ and revenue down 1.6% QoQ from Q1 FY27's ₹10.39 Cr PAT and ₹89.08 Cr revenue — so the YoY jump, not the QoQ number, is the real story this quarter; with revenue barely moving QoQ, the sequential comparison itself carries little signal beyond confirming the business has held its new, higher margin level.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹87.68 Cr-1.6%+4.4%
Expenses₹76.96 Cr+1.3%-1.6%
PAT₹10.49 Cr+0.92%+136.87%
Net margin11.5%0pp+6.3pp
EPS₹2.06+1%+136.8%

The entire YoY profit surge is a margin story rather than a volume story. Total expenses fell to 87.8% of revenue from 93.2% a year ago, lifting operating margin (OPM) to 13.8% from 8.6% YoY and net margin (NPM) to 11.5% from 5.3% YoY. Sequentially, margins eased slightly — OPM from 16.1% to 13.8% and NPM roughly flat at 11.5% vs 11.53% — as the expense ratio ticked up from 85.3% to 87.8% of revenue QoQ. EPS tracked the profit line: ₹2.06 this quarter versus ₹0.87 a year ago and ₹2.04 last quarter.

₹
90.4197.75105.1112.45119.7997.808-0308-2509-1710-1211-0411-06Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹97.8, down 12.5% over the past month of trading.

₹ Cr
03.927.8311.754.19Q1 FY26rev ₹60 Cr4.43Q2 FY26rev ₹84 Cr4.4Q3 FY26rev ₹75 Cr9.41Q4 FY26rev ₹104 Cr10.39Q1 FY27rev ₹89 Cr10.49Q2 FY27rev ₹88 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters.

Beyond the headline

What the summary numbers don't show

No exceptional items in either period — standalone and consolidated PAT differ by only ₹0.002 Cr

What management guided (1 FY-2026 call)
Management highlighted strong Q4 performance driven by both distribution and manufacturing segments, with revenue up 38% and EBITDA up 90%. The company expects continued revenue growth in the upcoming year, driven by new product additions and expanding end-user customer bases in both distribution and manufacturing. Whi

— This quarter: met

No brokerage estimates for Black Rose could be found in a web search (public trackers show zero analysts covering the stock), so there is no street print to grade against; vsStreet is unknown. Against the company's own May 2026 concall guidance — subdued near-term distribution demand offset by higher pricing and a strong merchant-export pipeline, plus a positive manufacturing/acrylamide export outlook — this quarter's combination of muted topline growth with sharp margin recovery is broadly on-script, so the result reads as a guidance-met quarter rather than a beat or miss. No separate management press release accompanied this filing to cross-check against. At the same board meeting (6 November 2026) the company also approved Srishti Gour's appointment as Company Secretary and Compliance Officer; the VP Innovation's resignation in October and the routine SEBI KYC/insider-trading-window items from September are unrelated to the financial print.

  • W1

    Whether the acrylamide export demand pickup flagged in the May 2026 concall lifts revenue growth beyond the current ~4% YoY pace

  • W2

    Status of the Specialty Amines project decision, which management said could come 'this year' (CY2026) as of the May 2026 call

  • W3

    Whether operating margin holds near the 13-14% level reached this quarter or reverts toward the prior ~8-9% YoY base as the B.R. Chemicals (Japan) wind-up concludes

Standalone and consolidated are nearly identical since the sole subsidiary (B.R. Chemicals Co., Japan) is being wound up and is reported as discontinued operations with a negligible ₹0.0021 Cr quarterly loss; no exceptional items in either comparative period.

Informational and educational content only. Not investment advice.